{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:38Z","timestamp":1793228258657,"version":"4.5.0"},"reference-count":201,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbcan.2026.189536","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:49:22Z","timestamp":1769186962000},"page":"189536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade"],"prefix":"10.1016","volume":"1881","author":[{"given":"Xiaodong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gouping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbcan.2026.189536_bb0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0010","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0020","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189536_bb0025","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/eji.200737772","article-title":"Historical insights into cytokines","volume":"37 (Suppl 1)","author":"Dinarello","year":"2007","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0040","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0045","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1038\/s41467-024-51496-2","article-title":"Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade","volume":"15","author":"Holzgruber","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0050","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","article-title":"Cholesterol induces CD8(+) T cell exhaustion in the tumor microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0060","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0065","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41423-025-01297-4","article-title":"Adjusting the scope of natural killer cells in cancer therapy","volume":"22","author":"Shen","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbcan.2026.189536_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01509-2","article-title":"Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery","author":"Murad","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0075","article-title":"Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity","volume":"5","author":"Shi","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"27","key":"10.1016\/j.bbcan.2026.189536_bb0080","doi-asserted-by":"crossref","first-page":"E2480","DOI":"10.1073\/pnas.1305394110","article-title":"Strength of PD-1 signaling differentially affects T-cell effector functions","volume":"110","author":"Wei","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0085","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-025-02241-8","article-title":"Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications","volume":"10","author":"Pu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189536_bb0090","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s12276-024-01301-3","article-title":"Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends","volume":"56","author":"Im","year":"2024","journal-title":"Exp. Mol. Med."},{"issue":"31","key":"10.1016\/j.bbcan.2026.189536_bb0095","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300895120","article-title":"Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies","volume":"120","author":"Lax","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189536_bb0100","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41416-024-02858-6","article-title":"Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study","volume":"131","author":"Castro-Espin","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0105","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0110","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1073\/pnas.0511161103","article-title":"Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor","volume":"103","author":"Stauber","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5769","key":"10.1016\/j.bbcan.2026.189536_bb0115","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"issue":"5187","key":"10.1016\/j.bbcan.2026.189536_bb0120","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1126\/science.7973659","article-title":"Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits","volume":"266","author":"Miyazaki","year":"1994","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0125","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","article-title":"IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients","volume":"107","author":"Ahmadzadeh","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189536_bb0130","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","article-title":"A first-in-human study and biomarker analysis of NKTR-214, a novel IL2R\u03b2\u03b3-biased cytokine, in patients with advanced or metastatic solid tumors","volume":"9","author":"Bentebibel","year":"2019","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189536_bb0140","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000673","article-title":"ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy","volume":"8","author":"Lopes","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189536_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010143","article-title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)","volume":"12","author":"Vaishampayan","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189536_bb0155","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0160","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1038\/s41467-022-32567-8","article-title":"Temporally restricted activation of IFN\u03b2 signaling underlies response to immune checkpoint therapy in mice","volume":"13","author":"Zemek","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0165","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1172\/JCI67008","article-title":"PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells","volume":"123","author":"West","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0175","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov."},{"issue":"30","key":"10.1016\/j.bbcan.2026.189536_bb0180","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results","volume":"41","author":"Diab","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010777","article-title":"Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1\/2 non-randomized ARTISTRY-1 trial","volume":"13","author":"Calvo","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"13","key":"10.1016\/j.bbcan.2026.189536_bb0190","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.bbcan.2026.189536_bb0195","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0200","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.immuni.2009.11.012","article-title":"Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells","volume":"32","author":"Pipkin","year":"2010","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0205","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1172\/JCI96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression","volume":"128","author":"Tang","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189536_bb0210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189536_bb0215","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J. Exp. Med."},{"issue":"5107","key":"10.1016\/j.bbcan.2026.189536_bb0220","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.8097338","article-title":"Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages","volume":"260","author":"Hsieh","year":"1993","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0225","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/1074-7613(94)90087-6","article-title":"Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors","volume":"1","author":"Dighe","year":"1994","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0230","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.bbcan.2026.189536_bb0235","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1200\/JCO.2007.15.6794","article-title":"Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma","volume":"26","author":"Daud","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189536_bb0240","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","article-title":"Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma","volume":"26","author":"Algazi","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189536_bb0245","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.annonc.2019.12.008","article-title":"Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients","volume":"31","author":"Algazi","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0250","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","article-title":"Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1","volume":"7","author":"Thomas","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0255","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.18632\/oncotarget.1853","article-title":"The immunocytokine NHS-IL12 as a potential cancer therapeutic","volume":"5","author":"Fallon","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","article-title":"First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors","volume":"25","author":"Strauss","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0265","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41551-022-00888-0","article-title":"Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker","volume":"6","author":"Mansurov","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"7693","key":"10.1016\/j.bbcan.2026.189536_bb0270","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0275","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/2326-6066.CIR-19-0359","article-title":"Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses","volume":"8","author":"Greaney","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189536_bb0280","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1200\/JCO.2007.13.3165","article-title":"Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma","volume":"26","author":"Sosman","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189536_bb0285","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-19-0972","article-title":"Intratumoral delivery of plasmid IL12 via electroporation leads to regression of injected and noninjected tumors in Merkel cell carcinoma","volume":"26","author":"Bhatia","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2026.189536_bb0290","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1200\/JCO.2020.38.15_suppl.3092","article-title":"A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral (iTu) injection alone and in combination with durvalumab","volume":"38","author":"Patel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2026.189536_bb0295","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2023.41.16_suppl.2521","article-title":"Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM)","volume":"41","author":"Montazeri","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0300","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0305","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"7528","key":"10.1016\/j.bbcan.2026.189536_bb0310","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0315","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1074-7613(02)00429-6","article-title":"IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells","volume":"17","author":"Dubois","year":"2002","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0320","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1074-7613(00)80664-0","article-title":"IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation","volume":"9","author":"Lodolce","year":"1998","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0325","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0330","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0335","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","article-title":"Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0340","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0345","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.bbcan.2026.189536_bb0350","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"48","key":"10.1016\/j.bbcan.2026.189536_bb0355","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0360","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid."},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2026.189536_bb0365","article-title":"957 NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study","volume":"9","author":"Altan","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0370","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors","volume":"24","author":"Miller","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189536_bb0375","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0380","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0385","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"issue":"7213","key":"10.1016\/j.bbcan.2026.189536_bb0390","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189536_bb0395","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189536_bb0400","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0405","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0410","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/0008-5472.CAN-14-3619","article-title":"Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors","volume":"76","author":"Baird","year":"2016","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189536_bb0415","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in combination with Pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0420","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma","volume":"8","author":"Bommareddy","year":"2019","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0425","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0430","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0435","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1038\/s41467-021-26112-2","article-title":"Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance","volume":"12","author":"Cao","year":"2021","journal-title":"Nat. Commun."},{"issue":"10183","key":"10.1016\/j.bbcan.2026.189536_bb0440","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"35","key":"10.1016\/j.bbcan.2026.189536_bb0445","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00632","article-title":"Phase Ib\/II study of pembrolizumab and pegylated-interferon alfa-2b in advanced melanoma","volume":"36","author":"Davar","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0450","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0455","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.bbcan.2026.189536_bb0460","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189536_bb0465","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0470","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189536_bb0475","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0480","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0485","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI67250","article-title":"Lung tumor NF-\u03baB signaling promotes T cell-mediated immune surveillance","volume":"123","author":"Hopewell","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189536_bb0490","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189536_bb0495","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1016\/j.celrep.2015.12.004","article-title":"Intratumoral LIGHT restores pericyte contractile properties and vessel integrity","volume":"13","author":"Johansson-Percival","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0500","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189536_bb0505","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.celrep.2019.10.092","article-title":"PD-1 signaling promotes control of chronic viral infection by restricting type-I-interferon-mediated tissue damage","volume":"29","author":"Raju","year":"2019","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0510","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189536_bb0515","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Rep."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189536_bb0520","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121062","article-title":"CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade","volume":"3","author":"Sato","year":"2018","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189536_bb0525","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrclinonc.2011.142","article-title":"Combination therapy: can less really be more in melanoma?","volume":"8","author":"Kirk","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0530","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","article-title":"High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma","volume":"10","author":"Lienard","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0535","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.ymthe.2022.04.008","article-title":"Development of a TNF-\u03b1-mediated Trojan Horse for bacteria-based cancer therapy","volume":"30","author":"Hu","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0540","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0545","doi-asserted-by":"crossref","first-page":"22311","DOI":"10.1038\/s41598-025-06348-4","article-title":"E3 ligase TRIM22 promotes melanoma proliferation by regulating cell cycle progression through K63-linked ubiquitination of p21","volume":"15","author":"Jin","year":"2025","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0550","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.celrep.2019.07.059","article-title":"Combination PD-1 and PD-L1 blockade promotes durable neoantigen-specific T cell-mediated immunity in pancreatic ductal adenocarcinoma","volume":"28","author":"Burrack","year":"2019","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0555","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.molcel.2019.12.012","article-title":"PD-1 imposes qualitative control of cellular transcriptomes in response to T cell activation","volume":"77","author":"Shimizu","year":"2020","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0560","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1172\/JCI125800","article-title":"An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition","volume":"129","author":"Naidoo","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0565","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007195","article-title":"Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis","volume":"11","author":"Badran","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"21","key":"10.1016\/j.bbcan.2026.189536_bb0570","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215181","article-title":"Infliximab for treatment of immune adverse events and its impact on tumor response","volume":"15","author":"Parvathareddy","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0575","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.stem.2024.04.018","article-title":"Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells","volume":"31","author":"Maulana","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0580","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI39143","article-title":"Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed","volume":"119","author":"Miller","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0585","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI99550","article-title":"IL-26 contributes to host defense against intracellular bacteria","volume":"129","author":"Dang","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189536_bb0590","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ymthe.2018.06.001","article-title":"Adenovirus coding for interleukin-2 and tumor necrosis factor alpha replaces lymphodepleting chemotherapy in adoptive T cell therapy","volume":"26","author":"Santos","year":"2018","journal-title":"Mol. Ther."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189536_bb0595","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184310","article-title":"Distinguishing between help and harm: helper T cell subsets and immune-related adverse events","volume":"134","author":"Haugh","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189536_bb0600","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1172\/JCI23215","article-title":"IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage","volume":"114","author":"O\u2019Garra","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189536_bb0605","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.1038\/ncomms8847","article-title":"IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis","volume":"6","author":"Nakamura","year":"2015","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0610","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1073\/pnas.0914500107","article-title":"IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection","volume":"107","author":"Brooks","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"47","key":"10.1016\/j.bbcan.2026.189536_bb0615","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu3624","article-title":"Antigen-specific B cell response regulation by IL-10-producing tolerogenic dendritic cells","volume":"11","author":"Morali","year":"2025","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0620","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ccell.2019.05.005","article-title":"Targeting tumors with IL-10 prevents dendritic cell-mediated CD8(+) T cell apoptosis","volume":"35","author":"Qiao","year":"2019","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0625","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.67","article-title":"Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","volume":"8","author":"Bhat","year":"2017","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189536_bb0630","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/mi.2013.103","article-title":"IL-10 modulates DSS-induced colitis through a macrophage-ROS-NO axis","volume":"7","author":"Li","year":"2014","journal-title":"Mucosal Immunol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189536_bb0635","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/mi.2013.97","article-title":"Contrasting immune responses mediate Campylobacter jejuni-induced colitis and autoimmunity","volume":"7","author":"Malik","year":"2014","journal-title":"Mucosal Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0640","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","article-title":"PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8(+) T cell invigoration and polyclonal T cell expansion in cancer patients","volume":"34","author":"Naing","year":"2018","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189536_bb0645","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/S1470-2045(19)30514-5","article-title":"Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial","volume":"20","author":"Naing","year":"2019","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.bbcan.2026.189536_bb0650","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0655","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jtho.2020.10.001","article-title":"Randomized phase 2 studies of checkpoint inhibitors alone or in combination with pegilodecakin in patients with metastatic NSCLC (CYPRESS 1 and CYPRESS 2)","volume":"16","author":"Spigel","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2026.189536_bb0660","doi-asserted-by":"crossref","first-page":"9563","DOI":"10.1200\/JCO.2020.38.15_suppl.9563","article-title":"Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1)","volume":"38","author":"Spigel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189536_bb0665","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.20.02232","article-title":"Randomized phase III study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA)","volume":"39","author":"Hecht","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0670","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10637-020-01000-6","article-title":"Immunologic and tumor responses of pegilodecakin with 5-FU\/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)","volume":"39","author":"Hecht","year":"2021","journal-title":"Invest. New Drugs"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189536_bb0675","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.immuni.2021.11.004","article-title":"Interleukin-10 receptor signaling promotes the maintenance of a PD-1(int) TCF-1(+) CD8(+) T cell population that sustains anti-tumor immunity","volume":"54","author":"Hanna","year":"2021","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189536_bb0680","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41590-024-01952-4","article-title":"Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption","volume":"25","author":"Pereira Ribeiro","year":"2024","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0685","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat. Immunol."},{"issue":"28","key":"10.1016\/j.bbcan.2026.189536_bb0690","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","article-title":"Proliferation marker Ki-67 in early breast cancer","volume":"23","author":"Urruticoechea","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2026.189536_bb0695","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1200\/JCO.2024.42.16_suppl.4569","article-title":"Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO)","volume":"42","author":"Gupta","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0700","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1073\/pnas.0409808102","article-title":"Regulation of hepcidin transcription by interleukin-1 and interleukin-6","volume":"102","author":"Lee","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0705","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41541-023-00766-z","article-title":"Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats","volume":"8","author":"Wang","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"649","key":"10.1016\/j.bbcan.2026.189536_bb0710","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abc0653","article-title":"Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses","volume":"13","author":"Gorby","year":"2020","journal-title":"Sci. Signal."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189536_bb0715","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0720","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"Pt 1","key":"10.1016\/j.bbcan.2026.189536_bb0725","first-page":"1","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0730","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/hep.1840120517","article-title":"Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6","volume":"12","author":"Castell","year":"1990","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0735","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses","volume":"268","author":"Jostock","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189536_bb0740","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1593\/neo.13706","article-title":"The IL-6\/JAK\/Stat3 feed-forward loop drives tumorigenesis and metastasis","volume":"15","author":"Chang","year":"2013","journal-title":"Neoplasia"},{"issue":"7152","key":"10.1016\/j.bbcan.2026.189536_bb0745","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature05970","article-title":"IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells","volume":"448","author":"Korn","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189536_bb0750","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0755","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1172\/JCI126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0760","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12916-022-02356-7","article-title":"Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189536_bb0765","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"28","key":"10.1016\/j.bbcan.2026.189536_bb0770","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at memorial Sloan Kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0775","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","article-title":"A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer","volume":"103","author":"Rossi","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0780","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1158\/1078-0432.CCR-13-2200","article-title":"A phase I\/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors","volume":"20","author":"Angevin","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0785","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005332","article-title":"Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)","volume":"10","author":"Johnson","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2026.189536_bb0790","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1200\/JCO.2024.42.16_suppl.9538","article-title":"Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma","volume":"42","author":"Weber","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189536_bb0795","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"314","key":"10.1016\/j.bbcan.2026.189536_bb0800","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189536_bb0805","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055718","volume":"12","author":"Nishina","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0810","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2026.189536_bb0815","doi-asserted-by":"crossref","first-page":"S869","DOI":"10.1016\/j.annonc.2021.08.1425","article-title":"1040O phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma","volume":"32","author":"Weber","year":"2021","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189536_bb0820","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0825","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bbcan.2026.189536_bb0830","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbi.2013.01.002","article-title":"Central inhibition of interleukin-6 trans-signaling during peripheral infection reduced neuroinflammation and sickness in aged mice","volume":"30","author":"Burton","year":"2013","journal-title":"Brain Behav. Immun."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0835","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005147","article-title":"Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors","volume":"10","author":"Sanborn","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189536_bb0840","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","article-title":"Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: a randomized, open-label, phase 3 trial","volume":"18","author":"Cho","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0845","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000664","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort","volume":"8","author":"Cho","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0850","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"7","author":"Bilusic","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"5172","key":"10.1016\/j.bbcan.2026.189536_bb0855","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.8036519","article-title":"Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog","volume":"265","author":"Cacalano","year":"1994","journal-title":"Science"},{"issue":"237","key":"10.1016\/j.bbcan.2026.189536_bb0860","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0865","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0870","first-page":"267","article-title":"Activation of extracellular signal-regulated kinase (ERK)1\/2 contributes to cytokine-induced apoptosis in purified rat pancreatic beta-cells","volume":"11","author":"Pavlovic","year":"2000","journal-title":"Eur. Cytokine Netw."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0875","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ccell.2021.04.011","article-title":"Interleukin-1 in tumor progression, therapy, and prevention","volume":"39","author":"Garlanda","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189536_bb0880","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661323","article-title":"Tumor NLRP3-derived IL-1\u03b2 drives the IL-6\/STAT3 axis resulting in sustained MDSC-mediated immunosuppression","volume":"12","author":"Tengesdal","year":"2021","journal-title":"Front. Immunol."},{"issue":"10105","key":"10.1016\/j.bbcan.2026.189536_bb0885","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.bbcan.2026.189536_bb0890","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-19-3176","article-title":"Inhibition of IL1\u03b2 by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial","volume":"80","author":"Wong","year":"2020","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0895","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.23.00980","article-title":"Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer: results from the CANOPY-1 trial","volume":"42","author":"Tan","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0900","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.23.00910","article-title":"Canakinumab as adjuvant therapy in patients with completely resected non-small-cell lung cancer: results from the CANOPY-A double-blind, randomized clinical trial","volume":"42","author":"Garon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0905","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189536_bb0910","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ccell.2024.10.014","article-title":"Interleukin-1\u03b1 release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity","volume":"42","author":"H\u00e4nggi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189536_bb0915","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3389\/fimmu.2019.01197","article-title":"IL-1 family members in cancer; two sides to every story","volume":"10","author":"Baker","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189536_bb0920","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189536_bb0925","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189536_bb0930","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1182\/blood-2007-02-075945","article-title":"Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses","volume":"111","author":"Hipp","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189536_bb0935","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients","volume":"15","author":"Ko","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189536_bb0940","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189536_bb0945","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189536_bb0950","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb0955","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189536_bb0960","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189536_bb0965","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase iii trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189536_bb0970","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with Ipilimumab versus Ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189536_bb0975","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000564","article-title":"Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with pretreated biliary tract cancer","volume":"8","author":"Yoo","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"24","key":"10.1016\/j.bbcan.2026.189536_bb0980","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-22-0346","article-title":"SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, for recurrent or metastatic cervical cancer: a clinical expansion cohort of a phase I study","volume":"28","author":"Feng","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189536_bb0985","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189536_bb0990","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8075","article-title":"Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy","volume":"8","author":"Jones","year":"2022","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189536_bb0995","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/2326-6066.CIR-19-0338","article-title":"Radiotherapy cooperates with IL15 to induce antitumor immune responses","volume":"8","author":"Pilones","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189536_bb1000","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189536_bb1005","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/s41590-024-01925-7","article-title":"Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity","volume":"25","author":"Santollani","year":"2024","journal-title":"Nat. Immunol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:38:48Z","timestamp":1782031128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":201,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0304419X26000089"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189536","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189536"}}